(Q44466191)

3 December 2017

title

Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia (English)

1 reference

3 December 2017

0 references

1

1 reference

3 December 2017

Brigitte Peters

2

1 reference

3 December 2017

Helmut Schroeder

3

1 reference

3 December 2017

Tobias Mann

4

1 reference

3 December 2017

Gerald Huether

5

1 reference

3 December 2017

Gisela Grecksch

6

1 reference

3 December 2017

publication date

1 June 2003

1 reference

3 December 2017

number of pages

14

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

inferred from page(s)

published in

1 reference

3 December 2017

volume

27

1 reference

3 December 2017

issue

4

1 reference

3 December 2017

page(s)

687-700

1 reference

The NMDA antagonist model for schizophrenia: promise and pitfalls.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Phencyclidine-induced psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Ketamine - reves et realites.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Illumination has no effect on rats' behavior in the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Brain region-specific changes in the expression of calcium sensor proteins after repeated applications of ketamine to rats

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Non-monotonic dependency of PPI on temporal parameters: differential alteration by ketamine and MK-801 as opposed to apomorphine and DOI.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Neurotransmitter interactions in schizophrenia-therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The entorhinal cortex-nucleus accumbens pathway and latent inhibition: a behavioral and neurochemical study in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

A revised excitotoxic hypothesis of schizophrenia: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

An integrated view of pathophysiological models of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Clinical and sensorimotor gating effects of ketamine in normals

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Subchronically applied phencyclidine fails to disrupt prepulse inhibition in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Stress in schizophrenia: an integrative view

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Disruption of latent inhibition in rats with postnatal hippocampal lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Alterations in the cortical serotonergic system in schizophrenia: a postmortem study.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The phencyclidine-glutamate model of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The changing roles and targets for animal models of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The neurobiology of startle

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The acoustic startle response in rats--circuits mediating evocation, inhibition and potentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Ketamine psychedelic therapy (KPT): a review of the results of ten years of research

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Ketamine activates psychosis and alters limbic blood flow in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Catching up on schizophrenia: natural history and neurobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Latent inhibition as a function of schizotypality and gender: implications for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Phencyclidine-induced abnormal behaviors in rats as measured by the hole board apparatus

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Phencyclidine-induced stereotyped behavior in rats: Dose response effects and antagonism by neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

A rat model of phencyclidine psychosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

NMDA receptor hypofunction model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Clinical features of latent inhibition in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

GABAergic neuronal subtypes in the human frontal cortex--development and deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

A proposed pathological model in the hippocampus of subjects with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Glutamate binding to brain membranes is increased in pentylenetetrazole-kindled rats

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The natural history and pathophysiology of treatment resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Latent inhibition in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The delayed effects of phencyclidine enhance amphetamine-induced behavior and striatal C-Fos expression in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

The switching model of latent inhibition: an update of neural substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Screening of antipsychotic drugs in animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900080-0

7 January 2021

10.1016/S0278-5846(03)00080-0

Identifiers

DOI

1 reference

3 December 2017

1 reference